COMMUNIQUÉS West-GlobeNewswire

Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting

14/06/2024 - 13:00

KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and positive immunomodulatory [...]

Generation Bio to Present at the 2024 TD Cowen Genetic Medicines & RNA Summit

14/06/2024 - 12:59

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO) a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff [...]

Greenwich LifeSciences Announces $2.5 Million Private Placement

14/06/2024 - 12:00

STAFFORD, Texas, June 14, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company" or "Greenwich"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO [...]

The Ensign Group, Inc. Declares Quarterly Dividend of $0.06 Per Share

14/06/2024 - 12:00

SAN JUAN CAPISTRANO, Calif., June 14, 2024 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]

Gain Therapeutics Announces Proposed Public Offering

13/06/2024 - 22:44

BETHESDA, Md., June 13, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain” or the “Company”) (Nasdaq: GANX) today announced that it is proposing to offer and sell, subject to market conditions, shares of its [...]

Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress

13/06/2024 - 22:40

- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . ( [...]

Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

13/06/2024 - 22:20

FARMINGDALE, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”) today announced financial results for the fiscal third quarter ended April 30, 2024. Third Quarter Highlights [...]

Vaxart Receives BARDA-Funded Project NextGen Award Valued Up to $453 Million to Conduct a Phase 2b Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate

13/06/2024 - 22:15

— 10,000-subject Phase 2b study will evaluate Vaxart’s next generation oral pill COVID-19 vaccine against an approved mRNA vaccine comparator — — Vaxart anticipates initiating enrollment as early as summer 2024 — SOUTH [...]

QIAGEN’s software QCI Interpret accelerates clinical reporting turnaround time for high throughput NGS testing labs

13/06/2024 - 22:05

Latest QCI Interpret release enhances performance of high-throughput NGS labs, improving turn-around time, diagnostic yield and quality of results // New features include bulk variant assessment, flagging of co- [...]

Beyond Air® Appoints David Webster as Chief Commercial Officer

13/06/2024 - 22:05

Mr. Webster brings more than 20 years of executive level experience in the life sciences industry GARDEN CITY, N.Y., June 13, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a [...]

Pliant Therapeutics Announces Appointment of Steve Krognes to Board of Directors

13/06/2024 - 22:05

SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of [...]

Xilio Therapeutics Appoints Aoife Brennan, M.D., and James Shannon, M.D., to its Board of Directors

13/06/2024 - 22:05

WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living [...]

Ocular Therapeutix™ Highlights Exceptional AXPAXLI™ SOL-1 Enrollment and Plans for Repeat Dosing Study (SOL-R) in wet AMD at Investor Day, Along with Positive 48-week Data from HELIOS NPDR Study

13/06/2024 - 22:05

151 subjects enrolled in various stages of loading and randomization in SOL-1 pivotal study of AXPAXLI in wet AMD as of June 7, 2024 Announces plans for SOL-R study to evaluate repeat doses of AXPAXLI in wet AMD 48-week [...]

Nkarta Adds Experienced Leader in Autoimmune R&D, George Vratsanos, M.D., FACR, to Board of Directors

13/06/2024 - 22:01

Senior R&D leader brings extensive expertise in immunology, clinical development and translational science SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage [...]

Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

13/06/2024 - 22:01

NEW YORK, June 13, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company committed to developing novel, transformative therapies for serious rare [...]

IN8bio Presents Positive Data Demonstrating Durable 1-year Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100

13/06/2024 - 22:01

100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy [...]

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

13/06/2024 - 22:01

LEXINGTON, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced that the company will participate in [...]

Precipio Inc. Announces Adjournment of Annual Meeting of Stockholders

13/06/2024 - 22:00

New Shareholders Meeting Date: Friday, June 21 at 9 a.m. Eastern Time NEW HAVEN, Conn., June 13, 2024 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. (NASDAQ: PRPO) , today announced that the company’s [...]

Nexalin Technology Announces Regulatory Approval to Sell Nexalin’s Gen-2, 15 mA Neurostimulation Device by the Brazilian Health Regulatory Agency (Anvisa)

13/06/2024 - 21:00

Brazil represents the 9th largest economy in the world with more than 35 million afflicted by mental health disorders HOUSTON, TX, June 13, 2024 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (the “Company” or “Nexalin [...]